# Transcrição: hsCRP_HDL_Mortality_Frontiers_2025

**Arquivo original:** hsCRP_HDL_Mortality_Frontiers_2025.pdf
**Extraído em:** 2026-02-05 01:35:27 UTC
**Caracteres:** 77977

---

```
                                                                                                                   TYPE Original Research
                                                                                                                   PUBLISHED 10 April 2025
                                                                                                                   DOI 10.3389/fendo.2025.1552219




                                                  hs-CRP/HDL-C can predict the
OPEN ACCESS                                       risk of all cause mortality in
EDITED BY
Xiaoying Ding,
Shanghai General Hospital, China
                                                  cardiovascular-kidney-metabolic
REVIEWED BY
Nihal Inandiklioğl,
                                                  syndrome stage 1-4 patients
Bozok University, Türkiye
Hiroya Ohta,                                      Fengjiao Han †, Haiyang Guo †, Hao Zhang and Yang Zheng*
Hokkaido University of Science, Japan
Belma Pojskic,                                    First Afﬁliated Hospital of Jilin University, Changchun, China
Medical Faculty University Zenica, Bosnia and
Herzegovina
Mohamed Hany,
Alexandria University, Egypt                      Background: The precise function of the hs-CRP/HDL-C ratio in forecasting the
*CORRESPONDENCE                                   long-term mortality risk of patients with stages 1-4 of Cardiovascular-Kidney-
Yang Zheng
                                                  Metabolic (CKM) syndrome remains inadequately delineated. This study
   zhengyang@jlu.edu.cn
                                                  investigates the potential correlation between the hs-CRP/HDL-C ratio and
†
  These authors have contributed equally to       long-term mortality risk in individuals with CKM syndrome stages 1-4.
this work and share ﬁrst authorship

RECEIVED 27 December 2024
                                                  Methods: This prospective cohort study utilises data from the China Health and
ACCEPTED 21 March 2025
PUBLISHED 10 April 2025
                                                  Retirement Longitudinal Study (CHARLS) project, encompassing 6,719 people
                                                  who satisﬁed stringent criteria. We developed three Cox proportional hazards
CITATION
Han F, Guo H, Zhang H and Zheng Y (2025)          regression models to investigate the potential relationship between the hs-CRP/
hs-CRP/HDL-C can predict the risk of all          HDL-C ratio and long-term mortality risk in patients with CKM stages 1-4. We
cause mortality in cardiovascular-kidney-
metabolic syndrome stage 1-4 patients.
                                                  employed Restricted Cubic Spline (RCS) curves for analysis to identify any
Front. Endocrinol. 16:1552219.                    potential nonlinear correlations. Furthermore, we performed Receiver
doi: 10.3389/fendo.2025.1552219                   Operating Characteristic (ROC) curve analysis to evaluate predictive
COPYRIGHT                                         performance and identify the appropriate cut-off value. To enhance the
© 2025 Han, Guo, Zhang and Zheng. This is an
open-access article distributed under the terms
                                                  research ﬁndings, we conducted a stratiﬁed analysis to investigate the
of the Creative Commons Attribution License       inﬂuence of various sociodemographic factors on this association.
(CC BY). The use, distribution or reproduction
in other forums is permitted, provided the
                                                  Results: In individuals with CKM syndrome stages 1-4, the 10-year incidence of
original author(s) and the copyright owner(s)
are credited and that the original publication    all-cause mortality was 14.1%. Upon controlling for additional potential
in this journal is cited, in accordance with      confounding variables, the outcomes of the Cox proportional hazards
accepted academic practice. No use,
distribution or reproduction is permitted         regression model distinctly demonstrated a statistically signiﬁcant linear
which does not comply with these terms.           positive association between the hs-CRP/HDL-C ratio and the long-term
                                                  mortality risk in patients. For each quartile increase in the hs-CRP/HDL-C ratio,
                                                  the probability of poor outcomes (i.e., mortality) escalated by 15% (Hazard Ratio,
                                                  HR = 1.15, 95% Conﬁdence Interval, CI: 1.09–1.22, p-value < 0.001). Moreover,
                                                  the integration of the hs-CRP/HDL-C ratio into the baseline risk prediction
                                                  model, with all pertinent factors thoroughly adjusted, markedly enhanced the
                                                  model’s predictive capacity, facilitating a more precise assessment of long-term
                                                  mortality risk in patients with CKM syndrome stages 1-4.




Frontiers in Endocrinology                                               01                                                           frontiersin.org
Han et al.                                                                                                                 10.3389/fendo.2025.1552219




                                                    Conclusion: This study identiﬁed a positive linear association between the hs-
                                                    CRP/HDL-C ratio and long-term mortality risk in patients with stages 1 to 4 of
                                                    CKM syndrome. This remarkable discovery not only offers a crucial reference for
                                                    enhancing early individualised treatment options but also greatly aids in the early
                                                    identiﬁcation of patients with poor prognoses, hence presenting a novel
                                                    perspective for improving clinical management pathways for these individuals.




                                                    KEYWORDS

                                                    cardiovascular-kidney-metabolic syndrome, high-sensitivity C-reactive protein, high-
                                                    density lipoprotein cholesterol, mortality, CHARLS




Introduction                                                                     promotes the accumulation of serum amyloid A and C-reactive
                                                                                 protein (CRP), thereby impairing HDL’s innate protective role
    The American Heart Association (AHA) President’s Council                     against atherosclerosis. This series of changes ultimately
Bulletin published in October 2023 formally designated                           exacerbates the abnormal efﬂux of cholesterol from cells, further
Cardiovascular-Kidney-Metabolic (CKM) syndrome as a systemic                     driving the progression of the disease (11–15). Recent studies have
and progressive illness state. The essence resides in the intricate              shown that the Atherogenic Index of Plasma (AIP), calculated
pathophysiological connections involving metabolic risk factors,                 through the logarithmic ratio of triglycerides (TG) to high-density
chronic kidney disease (CKD), and the cardiovascular system,                     lipoprotein cholesterol (HDL-C), can facilitate the progression of
including mechanisms including inﬂammation, oxidative stress,                    patients with CKM syndrome from stages 0-3 to stage 4 (16).
and insulin resistance. Over time, these degenerative processes                  Furthermore, research has found that the risk of mortality in stage 4
interact synergistically, facilitating the progression of atherosclerosis        of CKM syndrome is signiﬁcantly higher than that in stages 0-3
while inducing cardiac structural remodelling and a slow                         (17). Inﬂammatory indicators, including neutrophil count and
deterioration of renal function, so markedly elevating the mortality             high-sensitivity C-reactive protein (hs-CRP) levels, have
risk for patients (1, 2). Research indicates that around 5.3% of the             demonstrated predictive value for long-term prognosis in
adult population in the United States experiences concurrent cardiac,            cardiovascular disease patients (18, 19). Additionally, monocyte
kidney, and metabolic disorders, a demographic that typically                    and lymphocyte counts have also been found to predict mortality
receives insufﬁcient treatment, hence representing a burgeoning                  risk in CKD patients (20). Previous studies have delved into the
health issue (3).                                                                roles of inﬂammation, insulin resistance, and dyslipidemia in the
    Dyslipidaemia is a primary factor in the onset and advancement               pathophysiological processes of CKM (21–23). Overall, high levels
of Cardiovascular-Kidney-Metabolic (CKM) syndrome. Multiple                      of inﬂammatory markers and dyslipidemia are closely associated
studies have established that triglyceride (TG) and low-density                  with renal function deterioration and adverse cardiac prognosis in
lipoprotein cholesterol (LDL-C) levels serve as signiﬁcant                       CKD patients (5, 24).
predictors for the risk and prognosis of cardiovascular diseases                     Given the close correlation between inﬂammation and lipid
(CVD) (4–6). Furthermore, the triglyceride-glucose (TyG) index                   metabolism, numerous studies have integrated inﬂammatory and
and the estimated glucose disposal rate (eGDR) have also been                    metabolic indicators for comprehensive consideration. Prior studies
shown to increase the risk of cardiovascular diseases in patients with           have demonstrated that the monocyte to high-density lipoprotein
CKM syndrome stages 0-3, subsequently elevating their risk of                    cholesterol (HDL-C) ratio and the white blood cell count to HDL-C
mortality (7, 8). In contrast, high-density lipoprotein cholesterol              ratio can reliably forecast mortality in individuals with coronary
(HDL-C) has been conventionally viewed as a contributor to                       artery disease (25, 26). Additionally, the ratio of monocytes to HDL-
cholesterol efﬂux, endothelial protection, and antioxidant                       C is also closely associated with the incidence of cardiorenal
functions, with its levels negatively correlated to the onset of                 syndrome (27). The ratio of high-sensitivity C-reactive protein
cardiovascular disease (CVD) (9, 10). A study published in the                   (hs-CRP) to HDL-C, known as the hs-CRP/HDL-C ratio, has
American Journal of Kidney Diseases presents a paradox: In                       demonstrated prognostic signiﬁcance for cardiovascular illnesses
chronic kidney disease (CKD), a signiﬁcant decline in the activity               in middle-aged and elderly populations (28).
of key high-density lipoprotein (HDL)-related enzymes such as                        However, despite these studies revealing the signiﬁcant roles of
paraoxonase 1 (PON1), nitric oxide (NO) synthase (NOS), and                      inﬂammatory and lipid metabolic indicators in cardiovascular
LCAT results in a reduction of HDL-C’s functional activity,                      diseases, research on the speciﬁc association between the hs-CRP/
subsequently transitioning it into a proinﬂammatory state. This                  HDL-C ratio and all-cause mortality in patients with
state not only accelerates the oxidation of phospholipids but also               Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 1-4



Frontiers in Endocrinology                                                  02                                                          frontiersin.org
Han et al.                                                                                                                10.3389/fendo.2025.1552219




remains inadequate. Therefore, this study aims to deeply analyze              Advisory on Cardiovascular Disease and Stroke in Patients with
the relationship between the hs-CRP/HDL-C ratio and all-cause                 Cardiovascular-Kidney-Metabolic (CKM) Syndrome (1). The stages
mortality in patients with CKM stages 1-4, in order to provide new            are delineated as follows: Stage 1 is characterised by overweight/
insights and strategies for improving long-term prognosis in this             obesity, abdominal obesity, or dysfunctional adipose tissue in the
patient population.                                                           absence of other metabolic risk factors or chronic kidney disease
                                                                              (CKD); Stage 2 involves individuals exhibiting metabolic risk factors
                                                                              (hypertriglyceridemia [≥135 mg/dL], hypertension, metabolic
Materials and methods                                                         syndrome, diabetes) or CKD; Stage 3 encompasses subclinical
                                                                              cardiovascular disease (CVD), with subclinical CVD risk
Study population and data source                                              equivalents indicated by a high 10-year CVD risk in very high-risk
                                                                              CKD (CKD stages G4 or G5 or classiﬁed as very high risk by
     The China Health and Retirement Longitudinal Study                       KDIGO); Stage 4 pertains to individuals with excessive/
(CHARLS) is a nationally representative longitudinal survey. The              dysfunctional obesity, additional CKD risk factors, or clinical CVD
nationwide baseline survey of CHARLS was executed from June 2011              in the context of CKD. The Framingham Risk Score’s prediction of a
to March 2012, with participants being monitored biennially via face-         high 10-year cardiovascular disease risk functions as a risk equivalent
to-face Computer-Assisted Personal Interviews (CAPI). Physical                for subclinical cardiovascular disease (30). The estimated glomerular
assessments and blood samples are obtained during each biennial               ﬁltration rate (eGFR) is computed via the Chinese Modiﬁcation of
follow-up (29). The CHARLS data collection received approval from             Diet in Renal Disease (C-MDRD) equation (31) and classiﬁed into
the Peking University Biomedical Ethics Review Committee                      CKD stages according to Kidney Disease Improving Global
(IRB00001052-11015), and the research protocol complied with the              Outcomes (KDIGO) (1).
ethical criteria of the 1975 Helsinki Declaration. All participants in
the study granted their consent subsequent to obtaining
comprehensive written information.                                            Follow-up endpoint
     The ﬂowchart (Supplementary Figure S1) describes the
inclusion and exclusion criteria for this study. Initially, there were            The principal endpoint of this trial is deﬁned as all-cause
17,708 individual participants in the CHARLS baseline survey. We              mortality across the 10-year follow-up period, ascertained from
excluded 5,861 participants who lacked blood samples.                         the interview status (i.e., alive or died) of participants in waves 2, 3,
Additionally, we excluded participants missing key data such as               4, 5, and 6. Detailed information regarding interview dates is
age, height, weight, gender, hs-CRP, HDL-C, as well as those who              accessible from all three follow-up stages; however, precise data
were lost to follow-up (non-deceased) during the 2011-2020 follow-            on time of death is exclusively available in waves 2 and 6. Survival
up period and those with cancer at baseline, totaling 3,562                   time is deﬁned as the duration from the baseline survey date to the
exclusions. The remaining 8,285 participants were staged for                  date of the participant’s death, provided that the death event has
CKM, and 511 participants in stage 0 were also excluded, leaving              been adequately documented. In instances where precise mortality
7,466 participants. Further exclusions were made for participants             data is unavailable, we have conducted a reasonable calculation of
with hs-CRP/HDL-C values in the top 5% and bottom 5%.                         survival duration based on the median interval between the ﬁrst
Therefore, a total of 6,719 participants with CKM stages 1-4 were             interview date and the wave in which mortality information
included in the analysis.                                                     was documented.



Variables                                                                     Data collection

Calculation of hs-CRP/HDL-C ratio                                                 For this study, we systematically gathered the following data:
    In this study, the hs-CRP/HDL-C ratio was calculated by                   demographic details including age, gender, educational attainment,
dividing the hs-CRP level (mg/L) by the HDL-C level (mg/dL/                   and marital status; physiological measurements such as systolic
1000) (28). Participants were divided into four groups based on the           blood pressure (SBP), diastolic blood pressure (DBP), height,
quartiles of the hs-CRP/HDL-C ratio: Group 1 (Q1) with hs-CRP/                weight, and waist circumference; lifestyle factors regarding
HDL-C values ranging from 4.84 to 11.59; Group 2 (Q2) with hs-                smoking and alcohol consumption; and medical histories of
CRP/HDL-C values ranging from 11.59 to 22.27; Group 3 (Q3) with               hypertension, diabetes, dyslipidaemia, cancer, among others.
hs-CRP/HDL-C values ranging from 22.27 to 44.81; and Group 4                  Furthermore, biochemical markers such as glycated haemoglobin
(Q4) with hs-CRP/HDL-C values ranging from 44.81 to 219.                      A1c (HbA1C), fasting blood glucose (FBG), triglycerides (TG), total
                                                                              cholesterol (TC), high-density lipoprotein cholesterol (HDL-c),
Deﬁnition of CKM syndrome stage to 4                                          low-density lipoprotein cholesterol (LDL-c), blood urea nitrogen
    The staging of CKM syndrome ranges from 1 to 4, classiﬁed                 (BUN), serum creatinine (Scr), high-sensitivity C-reactive protein
according to the American Heart Association (AHA) Presidential                (hs-CRP), and uric acid (UA) were evaluated.




Frontiers in Endocrinology                                               03                                                              frontiersin.org
Han et al.                                                                                                            10.3389/fendo.2025.1552219




    Hypertension was deﬁned as follows: participants were                    Results
classiﬁed as hypertensive if they had a history of hypertension,
were undergoing particular treatment for hypertension, or had a              Baseline characteristics
systolic blood pressure (SBP) ≥140 mmHg or a diastolic blood
pressure (DBP) ≥90 mmHg at baseline (32). The diagnostic criteria                This study comprised a total of 6,719 participants from
for diabetes included participants reporting a history of diabetes or        CHARLS. Table 1 delineates the baseline characteristics of the
being treated for diabetes, or having an FBG ≥7.0 mmol/L (126 mg/            enrolled participants: the mean age was 59 years, with 52.5%
dL) or HbA1C ≥6.5% at baseline (33). Dyslipidemia was determined             identifying as female and 47.5% as male. Upon categorisation by
based on participants reporting a history of dyslipidemia or having          the quartiles of the hs-CRP/HDL-C ratio, we observed that persons
any one of the following: TG >2.26 mmol/L, TC >6.22 mmol/L,                  in the higher hs-CRP/HDL-C ratio groups exhibited increased
LDL-c >4.14 mmol/L, or HDL-c <1.04 mmol/L. Other medical                     proportions of hypertension, dyslipidaemia, diabetes mellitus,
conditions were determined based on participants’ self-reports.              cardiovascular disease, metabolic syndrome, as well as elevated
                                                                             rates of smoking and alcohol consumption (P < 0.05). Moreover,
                                                                             members of these groups demonstrated elevated levels of BMI, waist
Statistical analysis                                                         circumference, glycosylated haemoglobin, fasting blood glucose,
                                                                             total cholesterol, creatinine, uric acid, low-density lipoprotein
    The participants in this study were divided into four groups             cholesterol, and high-sensitivity C-reactive protein, alongside
(Q1-Q4) based on the quartiles of the hs-CRP/HDL-C ratio. For                diminished levels of high-density lipoprotein cholesterol and
continuous variables showing normal distribution, statistical data           eGFR, with statistically signiﬁcant differences (P < 0.05). No
were described using the mean and standard deviation, and analysis           signiﬁcant differences were seen among the four groups for
of variance (ANOVA) was used to infer differences between groups.            gender, education level, marital status, family residence, and the
For continuous variables not following a normal distribution,                existence of CKD (P-values > 0.05). Figure 1 illustrates the
statistical descriptions were made using the median and                      distribution of the hs-CRP/HDL-C ratio alongside the mortality
interquartile range, and the Kruskal-Wallis H test was used to               rate, with a median value of 22.27. The Kolmogorov-Smirnov (K-S)
examine differences between groups. Categorical variables were               test yielded a p-value < 0.05, signifying that the hs-CRP/HDL-C
characterized by frequency and percentage, and the c² test was               ratio has a skewed distribution. Figure 2 illustrates the comparison
used to assess differences between groups. Kaplan-Meier curves               of hs-CRP/HDL-C ratios between deceased and non-deceased
were employed to display mortality rates across different groups,            participants, revealing that deceased participants exhibited
and a Cox proportional hazards regression model was utilized to              elevated hs-CRP/HDL-C values compared to their non-deceased
explore the association between the hs-CRP/HDL-C ratio and all-              counterparts, with a statistically signiﬁcant difference.
cause mortality, with hazard ratios (HRs) and 95% conﬁdence
intervals (CIs) for patients with stages 1-4 CKM. Restricted cubic
spline regression for HRs was used to investigate the potential              The relationship between the hs-CRP/
nonlinear relationship between the hs-CRP/HDL-C ratio and all-               HDL-C ratio and all-cause mortality among
cause mortality in patients with stages 1-4 CKM. Additionally, we            participants with CKM stages 1-4
investigated whether the hs-CRP/HDL-C ratio could improve the
predictive performance of a baseline risk model, which included                   Initially, we constructed Kaplan-Meier survival curves to
age, gender, education level, marital status, current smoking status,        illustrate the all-cause mortality risk among various groups.
diabetes mellitus (DM), body mass index (BMI), fasting blood                 Figure 3 illustrates that patients in the Q4 group had markedly
glucose, and blood uric acid. Various measures were used to                  lower survival rates than the other three groups (Log-rank test P-
assess the incremental predictive performance of all-cause                   value < 0.001), although no signiﬁcant variations in survival rates
mortality risk after introducing the hs-CRP/HDL-C ratio into the             were detected among the Q1, Q2, and Q3 groups. The comparison of
baseline risk model, including the calculation of the C-statistic,           P values between groups is shown in Supplementary Table S1. We
continuous net reclassiﬁcation improvement (NRI), and integrated             additionally re-included participants with hs-CRP/HDL-C ratios in
discrimination improvement (IDI). The C-statistic was calculated to          the top 5% and bottom 5% (totalling 7,466 individuals) for Kaplan-
represent the performance of each model using the “Survival” R               Meier analysis, revealing no signiﬁcant alterations, hence afﬁrming
package. Both continuous NRI and IDI were calculated using the               the stability of our ﬁndings (Supplementary Figure S2).
“survIDINRI” R package. Finally, to explore the association between               In the 10-year follow-up period (2011-2020), there were 948
the hs-CRP/HDL-C ratio and all-cause mortality in patients with              fatalities among 6719 individuals with stages 1-4 CKM, yielding an
stages 1-4 CKM across different demographic characteristics,                 all-cause mortality rate of 14.1%. Three Cox proportional hazards
subgroup analyses and interaction analyses were conducted for                models were designed to precisely evaluate the relationship between
age, smoking status, education level, diabetes, metabolic syndrome,          the hs-CRP/HDL-C ratio and all-cause mortality in patients with
and CKM stage. All statistical analyses were performed using R               stages 1-4 CKM. Model 1 was adjusted solely for age and gender;
software (version 4.4.1), and a two-sided P-value < 0.05 was                 Model 2 included adjustments for age, gender, marital status,
considered statistically signiﬁcant.                                         educational attainment, BMI, smoking, and alcohol consumption,



Frontiers in Endocrinology                                              04                                                          frontiersin.org
Han et al.                                                                                                             10.3389/fendo.2025.1552219




TABLE 1 Baseline characteristics of individuals classiﬁed by hs-CRP/HDL quartiles.


                                                  Q1                   Q2                  Q3                 Q4
      Variable                 Level                                                                                                  p
                                             (4.84-11.56)         (11.56-22.27)       (22.27-44.81)       (44.81-219)
             n                                     1679                 1680                1679                1680

        Age,year                               58.77 (9.56)          59.32 (9.55)       59.88 (9.44)        60.64 (9.90)            <0.001

     Gender,n (%)              Female           907 (54.0)            882 (52.5)         866 (51.6)          872 (51.9)              0.500

                                 Male           772 (46.0)            798 (47.5)         813 (48.4)          808 (48.1)

   Education,n (%)      primary or below        1532 (91.2)          1536 (91.4)         1514 (90.2)         1532 (91.2)             0.615

                        second/high school
                                                 147 (8.8)            144 (8.6)           164 (9.8)           148 (8.8)
                             or above

     Marital,n (%)             married          1481 (88.2)          1485 (88.4)         1470 (87.6)         1447 (86.1)             0.182

                              unmarried         198 (11.8)            195 (11.6)         209 (12.4)          233 (13.9)

      HTN,n (%)                   no            1061 (63.6)          1020 (60.9)         899 (53.6)          785 (46.9)             <0.001

                                 yes            608 (36.4)            654 (39.1)         779 (46.4)          888 (53.1)

       DM,n (%)                   no            1500 (89.7)          1460 (87.1)         1387 (82.8)         1310 (78.2)            <0.001

                                 yes            173 (10.3)            216 (12.9)         289 (17.2)          366 (21.8)

       DL,n (%)                   no            1159 (69.8)           970 (58.3)         786 (47.3)          649 (38.9)             <0.001

                                 yes            502 (30.2)            693 (41.7)         874 (52.7)          1021 (61.1)

      CKD,n (%)                   no            1544 (92.5)          1564 (93.3)         1562 (93.4)         1577 (94.0)             0.405

                                 yes             125 (7.5)            113 (6.7)           111 (6.6)           101 (6.0)

      CVD,n (%)                   no            1473 (87.7)          1460 (86.9)         1427 (85.0)         1401 (83.4)             0.001

                                 yes            206 (12.3)            220 (13.1)         252 (15.0)          279 (16.6)

      MetS,n (%)                  no            1544 (92.3)          1397 (83.2)         1246 (74.6)         1071 (64.0)            <0.001

                                 yes             129 (7.7)            282 (16.8)         425 (25.4)          603 (36.0)

   Take medicine for
                                  no            1640 (97.7)          1628 (96.9)         1616 (96.2)         1583 (94.2)            <0.001
    diabetes,n (%)

                                 yes             39 (2.3)              52 (3.1)           63 (3.8)            97 (5.8)

  Take medicine for
                                  no            1458 (86.8)          1389 (82.7)         1286 (76.6)         1194 (71.1)            <0.001
  hypertension,n (%)

                                 yes            221 (13.2)            291 (17.3)         393 (23.4)          486 (28.9)

  Take medicine for
                                  no            1662 (99.0)          1665 (99.1)         1657 (98.7)         1654 (98.5)             0.291
  dyslipidemia,n (%)

                                 yes             17 (1.0)              15 (0.9)           22 (1.3)            26 (1.5)

    Lives in rural or
                        Urban Community         495 (29.5)            516 (30.7)         565 (33.7)          616 (36.7)             <0.001
      urban,n (%)

                             Rural Village      1184 (70.5)          1164 (69.3)         1114 (66.3)         1064 (63.3)

   Annual household
                                             21002.7 (30853.5)    21102.7 (29291.8)   21304.5 (45703.2)   22106.9 (33644.6)          0.882
     income,RMB

    Mortality,n (%)               no            1476 (87.9)          1471 (87.6)         1454 (86.6)         1369 (81.5)            <0.001

                                 yes            203 (12.1)            209 (12.4)         225 (13.4)          311 (18.5)

    Smoking,n (%)             Ex-smoker          114 (6.8)            146 (8.7)           148 (8.8)          191 (11.4)              0.001

                             Non-smoker         1025 (61.2)          1005 (59.8)         994 (59.2)          976 (58.2)

                               smoker           537 (32.0)            529 (31.5)         537 (32.0)          511 (30.5)

                                                                                                                                       (Continued)




Frontiers in Endocrinology                                               05                                                         frontiersin.org
Han et al.                                                                                                                                                  10.3389/fendo.2025.1552219




TABLE 1 Continued


                                                               Q1                         Q2                           Q3                          Q4
       Variable                     Level                                                                                                                                         p
                                                          (4.84-11.56)               (11.56-22.27)                (22.27-44.81)                (44.81-219)
     Drinking,n (%)                    no                    1061 (63.2)                 1095 (65.2)                  1158 (69.0)                 1169 (69.6)                  <0.001

                                       yes                    618 (36.8)                  585 (34.8)                   521 (31.0)                 511 (30.4)

          eGFR                                              107.02 (26.11)              105.74 (26.97)              103.03 (27.49)              102.13 (31.81)                 <0.001

       BMI, kg/m2                                            22.56 (3.31)                23.54 (3.70)                 24.21 (3.72)                24.79 (4.21)                 <0.001

        Waist
                                                             81.75 (11.07)              84.13 (11.77)                86.65 (11.70)               88.32 (13.06)                 <0.001
    measurement,cm

       Sbp,mmHg                                             128.82 (21.22)              130.20 (20.77)              132.46 (21.63)              135.22 (22.21)                 <0.001

       Dbp,mmHg                                              74.73 (12.10)              75.65 (11.86)                76.68 (12.42)               77.94 (12.11)                 <0.001

      Glycated
                                                              5.16 (0.68)                 5.24 (0.73)                 5.32 (0.87)                 5.42 (0.99)                  <0.001
   hemoglobin,mg/dl

     Glucose,mg/dl                                          104.84 (25.24)              108.37 (30.16)              112.61 (40.18)              118.11 (47.88)                 <0.001

        TG,mg/dl                                            105.19 (57.88)              126.18 (85.95)              148.28 (110.60)             170.33 (154.17)                <0.001

        TC,mg/dl                                            194.58 (36.19)              193.42 (37.70)              197.79 (40.03)              194.69 (41.49)                  0.009

      LDL-C,mg/dl                                           117.37 (32.51)              118.07 (34.00)              120.13 (36.38)              115.76 (38.15)                  0.004

    Creatinine,mg/dl                                          0.76 (0.18)                 0.77 (0.18)                 0.80 (0.26)                 0.81 (0.34)                  <0.001

     Uric acid,mg/dl                                          4.19 (1.18)                 4.39 (1.21)                 4.58 (1.23)                 4.76 (1.31)                  <0.001

      hs-CRP,mg/L                                             0.47 (0.15)                 0.84 (0.26)                 1.50 (0.51)                 3.83 (2.08)                  <0.001

      HDL-C,mg/dl                                            58.06 (14.51)              51.51 (13.51)                47.91 (13.56)               43.85 (13.10)                 <0.001

Data were expressed as mean ( SD) or n (%).HTN hypertension, DM diabetes, DL dyslipidemia, CKD chronic Kidney Disease, CVD cardiovascular disease, Mets metabolic Syndrome, eGFR
Estimated Glomerular Filtration Rate, BMI body mass index, Sbp systolic blood pressure, Dbp diastolic pressure, TG triglyceride, TC total cholesterol, LDL-C low-density lipoprotein cholesterol,
hs-CRP hypersensitive C-Reactive Protein, HDL-C high-density lipoprotein cholesterol.




    FIGURE 1
    Distribution of hs-CRP/HDL.




Frontiers in Endocrinology                                                                    06                                                                               frontiersin.org
Han et al.                                                                                                                   10.3389/fendo.2025.1552219




   FIGURE 2
   Analysis of inter group differences in hs-CRP/HDL values between mortality and non mortality groups. (*indicates p < 0.05).




annual household income and lives in rural or urban; Model 3                     annual household income, lives in rural or urban, diabetes,
represented the fully adjusted model, encompassing all potential                 hypertension, triglycerides, medication history, fasting blood
confounding variables, namely age, gender, marital status,                       glucose, low-density lipoprotein cholesterol, uric acid, total
educational attainment, BMI, smoking, alcohol consumption,                       cholesterol, and blood creatinine. Table 2 demonstrates that in




   FIGURE 3
   Kapla-Meier estimates 10-year survival rate of CKM1-4 participants based on hs-CRP/HDL quartile grouping.




Frontiers in Endocrinology                                                  07                                                            frontiersin.org
Han et al.                                                                                                                                                10.3389/fendo.2025.1552219




TABLE 2 The correlation between hs-CRP/HDL and ten-year mortality risk in CKM syndrome stage 1-4 population.


                                                Model 1                                              Model 2                                                Model 3
      Variables
                                 HR (95%)                     P value                  HR (95%)                     P value                  HR (95%)                     P value
      hs-CRP/HDL
                                1.13 (1.08,1.19)                <0.001                1.16 (1.10,1.22)                <0.001                1.15 (1.09,1.22)                <0.001
        per IQR

     hs-CRP/
    HDL quartile

             Q1                                     ref                                                   ref                                                    ref

             Q2                 0.99 (0.81,1.20)                 0.90                 1.05 (0.84,1.32)                 0.65                 1.06 (0.84,1.34)                  0.63

             Q3                 1.05 (0.87,1.28)                 0.58                 1.19 (0.95,1.49)                 0.12                 1.17 (0.93,1.47)                  0.18

             Q4                 1.40 (1.17,1.67)                <0.001                1.61 (1.30,1.99)                <0.001                1.55 (1.24,1.93)                <0.001

Table 2 The correlation between hs-CRP/HDL and ten-year mortality risk in CKM syndrome stage 1-4 population.
Model 1: adjusted age, gender.
Model 2: adjusted age, gender, marital, bmi, smoking, drinking, education, Annual household income and Lives in rural or urban.
Model 3: age, gender, marital, bmi, smoking, drinking, education, Annual household income, Lives in rural or urban, DM, HTN, medication history, triglycerides, glucose, ldl cholesterol, uric
acid, total cholesterol and creatinine.


the fully adjusted model, each quartile increase in the hs-CRP/                                   signifying a 55% elevated risk of all-cause mortality for Q4
HDL-C ratio correlated with a 15% elevation in mortality risk                                     participants relative to Q1 participants, with a statistically
(HR = 1.15, 95% CI: 1.09–1.22, p<0.001). To clarify the association                               signiﬁcant distinction. Nonetheless, in all three models, no
between the hs-CRP/HDL-C ratio and all-cause mortality in                                         statistically signiﬁcant changes in all-cause mortality risk were
individuals with CKM stages 1-4, the hs-CRP/HDL-C ratio was                                       observed between individuals in the second quartile (Q2) and
categorized into quartiles. In the comprehensively adjusted Model                                 third quartile (Q3) as compared to those in the ﬁrst quartile (Q1)
3, participants in the fourth quartile (Q4) of the hs-CRP/HDL-C                                   (P>0.05). We re-included participants with hs-CRP/HDL ratios in
ratio exhibited a hazard ratio (HR) of 1.55 (95% CI: 1.24–1.93,                                   the top 5% and bottom 5% (totaling 7,466 individuals) for COX
P<0.001) when compared to those in the ﬁrst quartile (Q1),                                        regression analysis and observed no signiﬁcant alterations in the




    FIGURE 4
    Limited cubic splines (RCS). The shaded area is speciﬁc to age, gender, marital status BMI,The smoking and drinking situation, hypertension, diabetes,
    and dyslipidemia were adjusted. There is no non-linear correlation. P for total< 0.001, P for nonlinear=0.187.




Frontiers in Endocrinology                                                                   08                                                                             frontiersin.org
Han et al.                                                                                                                    10.3389/fendo.2025.1552219




   FIGURE 5
   Receiver operating curve for hs-CRP/HDL. AUC,Area under the curve.




   FIGURE 6
   Grouping of CKM1-4 participants based on ROC analysis of the binary indicator of the optimal critical value of 10-year survival rate for hs-CRP/
   HDL quartiles.




Frontiers in Endocrinology                                                  09                                                               frontiersin.org
Han et al.                                                                                                                                             10.3389/fendo.2025.1552219




TABLE 3 Added predictive ability and reclassiﬁcation statistics of hs-CRP/HDL.


 Variables                C-statistic (95% CI)              P value             IDI (95% CI)              P value              Continuous NRI (95% CI)             P value
 Baseline risk model           0.753(0.719,0.787)                  ref                    ref                    ref                            ref                     ref

    +hs-CRP/HDL                0.760(0.726,0.794)                0.032          0.009(0.0004 - 0.017)           0.041                  0.296 (0.155 - 0.437)           <0.001

Baseline risk model: age, gender, education, marital status, current smoking status, DM, BMI, Fasting blood glucose and blood uric acid.


risk estimates, so afﬁrming the robustness of our ﬁndings                                        markedly inferior to that of patients with a low hs-CRP/HDL-C
(Supplementary Table S2).                                                                        ratio, as illustrated by the Kaplan-Meier survival curve in Figure 6
     Subsequently, we used limited cubic splines (RCS) to ascertain                              (Log-rank test P-value < 0.001). The baseline risk model forecasting
the presence of a nonlinear relationship between the hs-CRP/HDL-                                 the 10-year all-cause mortality risk in patients with stages 1-4 CKM
C ratio and all-cause mortality in people with CKM stages 1-4.                                   demonstrated exceptional concordance between observed and
Figure 4 illustrates the absence of a nonlinear relationship between                             anticipated probabilities (see to Supplementary Figure S3 for
the hs-CRP/HDL-C ratio and all-cause mortality in patients with                                  details). Table 3 illustrates that the inclusion of the hs-CRP/HDL-
CKM stages 1-4 (P for total < 0.001, P for nonlinear = 0.187). An                                C ratio in the baseline risk model markedly enhanced its predictive
elevation in the hs-CRP/HDL-C ratio correlated with a notable                                    capability, as seen by an increase in the C-statistic from 0.753 to
increase in all-cause mortality among persons with CKM stages 1-4.                               0.760 (P = 0.032). This outcome signiﬁcantly underscores the
     ROC analysis was employed to ascertain the appropriate cut-off                              relevance of the hs-CRP/HDL-C ratio in prognostication.
value of the hs-CRP/HDL-C ratio for predicting the risk of all-cause                             Furthermore, the integration of the hs-CRP/HDL-C ratio into the
death. The research determined an appropriate cut-off value of 32.6,                             baseline risk model resulted in notable improvements in net
exhibiting a sensitivity of 43.8% and a speciﬁcity of 66.4%. Figure 5                            reclassiﬁcation improvement (NRI) and integrated discrimination
illustrates that the area under the curve (AUC) was 0.561 (95% CI                                improvement (IDI) (P < 0.05), thereby reinforcing the signiﬁcance
0.541-0.582). The hs-CRP/HDL-C ratio, utilised as a dichotomous                                  of the hs-CRP/HDL-C ratio in forecasting the risk of all-cause
indicator according to the optimal cut-off value for all-cause                                   mortality in individuals with stages 1-4 CKM.
mortality established through ROC analysis, revealed that the 10-                                    Finally, we conducted subgroup analyses and interaction analyses
year survival rate for patients with a high hs-CRP/HDL-C ratio was                               for age, smoking status, education level, DM, HTN, MetS, and CKM




    FIGURE 7
    Association between hs-CRP/HDL (per quartile increase) in different subgroups and 10-year mortality risk in CKM syndrome stage 1-4 participants.




Frontiers in Endocrinology                                                                  10                                                                      frontiersin.org
Han et al.                                                                                                               10.3389/fendo.2025.1552219




stages. As shown in the ﬁgures, the results (Figure 7) indicated that          individuals (37). A separate study indicated that an elevated hs-
there was only an interaction between the presence or absence of               CRP/HDL-C ratio serves as a signiﬁcant independent risk factor for
hypertension (interaction P = 0.013). No interactions were observed            cardiovascular disease, stroke incidence, and cardiac issues (28).
in other subgroups (interaction P > 0.05).                                     The hs-CRP/HDL-C ratio is substantially correlated with adverse
                                                                               clinical outcomes in patients with acute ischaemic stroke (38).
                                                                                   Hypersensitive C-reactive protein (hs-CRP), traditionally
Discussion                                                                     regarded as a reactant in the acute phase of inﬂammation and
                                                                               mainly synthesized in hepatocytes, has increasingly been shown in
     This research is a prospective cohort study involving 6,719               recent studies to also express its mRNA and protein in arterial
eligible people, investigating the potential relationship between the          plaque tissue, with levels 10 times higher than in normal arterial
hs-CRP/HDL-C ratio and the risk of all-cause death within the                  tissue, resulting in locally much higher concentrations of hs-CRP in
framework of CKM syndrome for the ﬁrst time. The study ﬁndings                 plaques compared to those in plasma. Locally in the arteries, hs-
indicated a substantial positive association between the hs-CRP/               CRP not only inhibits the release of nitric oxide (NO) and vascular
HDL-C ratio and the probability of all-cause mortality in patients             dilation but also enhances NADPH oxidase activity in the arterial
with stages 1-4 CKD. The Kaplan-Meier curves demonstrate that                  endothelium, promoting the generation of superoxide and
the survival rate of patients in the Q4 group is signiﬁcantly lower            subsequently triggering endothelial dysfunction, thereby exerting
than that of the other three groups. To further elucidate the dose-            pro-inﬂammatory and pro-atherosclerotic effects (39).
response relationship between the two, additional Cox regression               Furthermore, hs-CRP stimulates macrophages to secrete
analysis was conducted, revealing that for every increase in the hs-           inﬂammatory cytokines such as interleukin-8 (IL-8), interleukin-6
CRP/HDL-C ratio across one quartile, the risk of death increases by            (IL-6), and tumor necrosis factor (TNF) (40). Among these, IL-6
14%. However, when considering the hs-CRP/HDL-C ratio as a                     has been shown to upregulate the expression of cell adhesion
categorical variable, statistically signiﬁcant differences were only           molecules, leading to persistent damage to endothelial barrier
observed between Q1 and Q4. The Restricted Cubic Splines (RCS)                 function (41).
curves conﬁrmed the absence of a nonlinear relationship, leading us                 Conversely, high-density lipoprotein (HDL) serves several
to conclude that there is a positive linear correlation between the hs-        protective functions in atherosclerosis prevention. HDL
CRP/HDL-C ratio and all-cause mortality. ROC curve analysis                    signiﬁcantly mitigates the onset and progression of atherosclerosis
revealed an appropriate cut-off value of 32.6 for the hs-CRP/                  by reversing cholesterol transport, displaying antioxidant
HDL-C ratio. Moreover, our investigation revealed that the                     properties, demonstrating anti-inﬂammatory actions, providing
inclusion of the hs-CRP/HDL-C ratio as a variable in the baseline              anti-thrombotic effects, and enhancing endothelial function
prediction model markedly enhanced the model’s accuracy in                     (42, 43). The antioxidant properties of HDL primarily rely on its
forecasting the probability of all-cause death in patients with                protein constituents, apolipoprotein AI (apo AI) and paraoxonase 1
stages 1-4 CKM.                                                                (arylesterase, EC 3.1.8.1). Paraoxonase 1, an enzyme carried by
     The deterioration of Cardiovascular-Kidney-Metabolic (CKM)                HDL components, prevents the oxidative alteration of low-density
syndrome health status frequently heralds an elevated risk of                  lipoprotein (LDL), hence obstructing a crucial step in
premature mortality and heightened morbidity. The interplay                    atherosclerosis formation (44, 45).
between lipid metabolism and inﬂammatory responses plays a                          However, recent research has revealed that HDL particles are
pivotal role in augmenting the burden of cardiovascular diseases               highly heterogeneous. Normal HDL (nHDL) exhibits a positive
(CVDs) and accelerating renal dysfunction. Disruptions in lipid                promotional effect on angiogenesis, emphasizing its role in
metabolism exacerbate tubular injury and propel the progression of             maintaining vascular health. In contrast, HDL present in patients
interstitial ﬁbrosis. Notably, the resultant oxidized high-density             with coronary artery disease (CAD), termed dysfunctional HDL
lipoprotein (Ox-HDL) can induce proinﬂammatory pathways,                       (dHDL), exhibits a dysfunctional state that not only fails to perform
encompassing the upregulation of tumor necrosis factor-alpha                   its normal physiological functions but also impairs angiogenesis.
(TNF-a), CC motif chemokine 2, while also augmenting reactive                  This ﬁnding challenges the traditional view that HDL solely
oxygen species (ROS) generation and exerting direct toxic effects on           possesses anti-atherosclerotic properties, revealing the dual nature
the kidney parenchyma (34–36). Furthermore, the deterioration of               of HDL in the atherosclerotic process—both potentially pro-
CKM health status is largely attributable to the substantial burden            atherosclerotic and anti-atherosclerotic. These studies also suggest
of CVDs (1). The hs-CRP/HDL-C ratio, as a novel inﬂammatory-                   that simply increasing HDL levels is not sufﬁcient to ensure a
lipid complex index, has been conﬁrmed by multiple studies to be               reduction in cardiovascular disease risk (46, 47). They highlight the
an important biomarker for the occurrence and development of                   complex roles of hs-CRP and HDL in the pathophysiology of
CVD. Yano et al. demonstrated a signiﬁcant correlation between the             atherosclerosis, providing new insights into understanding the
ratio of high-density lipoprotein cholesterol to C-reactive protein            pathogenesis of CKM syndrome.
and left ventricular diastolic function as well as right ventricular                Hypersensitive C-reactive protein (hs-CRP) and high-density
systolic function in patients with heart failure with preserved                lipoprotein cholesterol (HDL-C) are regarded as critical biomarkers
ejection fraction, suggesting that this ratio may serve as a                   of inﬂammation and endothelial dysfunction, respectively, serving
predictor for all-cause and cardiogenic mortality risk in these                opposing functions in the modulation of inﬂammatory responses—



Frontiers in Endocrinology                                                11                                                          frontiersin.org
Han et al.                                                                                                               10.3389/fendo.2025.1552219




hs-CRP facilitates inﬂammation, whereas HDL-C may suppress                     over 45 years old in China, and additional validation is needed to
it. These two biomarkers collaboratively engage in the                         assess the generalizability of these ﬁndings to other racial groups
pathophysiological mechanisms that contribute to the emergence                 and age groups. Secondly, the diagnosis of chronic diseases relies on
of cardiorenal-metabolic (CKM) syndrome, indicating that this                  self-reporting by subjects, which may introduce bias. Thirdly, the
inﬂammatory-lipid complex may serve as a signiﬁcant predictor                  CHARLS dataset has room for improvement in recording the
of long-term mortality risk in patients with CKM syndrome. Our                 causes of patient deaths. We only considered all-cause
study conﬁrms this assertion, demonstrating that the long-term                 mortality among patients and lacked research on the risk of
mortality risk in patients with CKM syndrome, increases                        cardiovascular death.
signiﬁcantly with elevated hs-CRP/HDL-C ratios, exhibiting a
positive linear correlation between the two. We hypothesize that
this association may stem from the following two factors: Firstly, as          Conclusion
an inﬂammatory marker, elevated hs-CRP levels reﬂect heightened
inﬂammatory responses in the body, which may further exacerbate                    This cohort study demonstrates a substantial linear relationship
renal damage and facilitate the progression of cardiovascular                  between the hs-CRP/HDL-C ratio and long-term all-cause
diseases. Secondly, High-Density Lipoprotein (HDL) plays a                     mortality in patients with stages 1-4 of CKM syndrome. This
crucial role in reverse cholesterol transport, aiding in the removal           discovery indicates that a comprehensive evaluation of the hs-
of excess cholesterol from peripheral tissues back to the liver for            CRP/HDL-C ratio may serve as a more effective and efﬁcient
metabolism and excretion. However, in patients with CKM                        screening instrument for identifying high-risk patients with stages
syndrome, HDL functionality is often impaired, resulting in                    1-4 of CKM syndrome. Moreover, as an easily obtainable and
decreased cholesterol transport capacity and subsequent lipid                  economical biomarker, this ratio exhibits signiﬁcant potential in
accumulation, which may accelerate renal function deterioration                prognostic evaluation.
and promote atherosclerosis development. Consequently, an
increased hs-CRP/HDL-C ratio may indicate intensiﬁed
inﬂammatory responses and lipid accumulation in the body,                      Data availability statement
thereby elevating the long-term all-cause mortality risk in patients
with CKM syndrome stages 1-4. This study not only solidiﬁes the                   The datasets presented in this study can be found in online
hs-CRP/HDL-C ratio’s role as a predictive factor but also                      repositories. The names of the repository/repositories and accession
demonstrates its capacity to enhance the precision of clinical                 number(s) can be found below: http://charls.pku.edu.cn.
prognostic predictions. Thus, the hs-CRP/HDL-C ratio may serve
as a signiﬁcant biomarker for identifying high-risk individuals and
aiding therapeutic decision-making, offering new insights for risk             Ethics statement
stratiﬁcation and personalized therapy of CKM syndrome patients.
     The strengths of our research are outlined below: Firstly, our                The studies involving humans were approved by the Peking
study is a prospective cohort study with a large sample size,                  University Biomedical Ethics Review Committee. The studies were
distinguished by its systematic assessment of the association                  conducted in accordance with the local legislation and institutional
between the hs-CRP/HDL-C ratio and long-term adverse                           requirements. The participants provided their written informed
prognosis in CKM syndrome patients, and an in-depth                            consent to participate in this study. Written informed consent was
exploration of the speciﬁc manifestations of this association. This            obtained from the individual(s), and minor(s)’ legal guardian/next
innovative aspect not only ﬁlls a research gap in this ﬁeld but also           of kin, for the publication of any potentially identiﬁable images or
provides important reference material for subsequent studies.                  data included in this article.
Secondly, in terms of study design, we analyzed the hs-CRP/
HDL-C ratio both as a categorical variable (divided by quartiles)
and as a continuous variable to comprehensively evaluate its
association with the risk of all-cause mortality. This analytical
                                                                               Author contributions
strategy not only helps to identify risk differences at different
                                                                                   FH: Writing – original draft, Writing – review & editing. HG:
levels of hs-CRP/HDL-C but also better reﬂects clinical realities.
                                                                               Writing – original draft, Writing – review & editing. HZ: Writing –
Thirdly, hs-CRP and HDL-C, as test indicators, have the advantages
                                                                               review & editing. YZ: Writing – review & editing.
of simple and easy detection, accessibility, and relatively low cost.
These characteristics make them highly valuable in clinical practice,
especially in primary health care. Lastly, to ensure the credibility of
our results, we conducted sensitivity studies, which conﬁrmed the              Funding
reliability of our research.
     However, this study also has certain limitations. Firstly, our                The author(s) declare that no ﬁnancial support was received for
research is focused solely on middle-aged and elderly individuals              the research and/or publication of this article.




Frontiers in Endocrinology                                                12                                                          frontiersin.org
Han et al.                                                                                                                                           10.3389/fendo.2025.1552219




Acknowledgments                                                                                 Publisher’s note
  The authors acknowledge the contributions of all members of                                       All claims expressed in this article are solely those of the authors
CHALRS and the participants who contributed their data.                                         and do not necessarily represent those of their afﬁliated
                                                                                                organizations, or those of the publisher, the editors and the
                                                                                                reviewers. Any product that may be evaluated in this article, or
Conﬂict of interest                                                                             claim that may be made by its manufacturer, is not guaranteed or
                                                                                                endorsed by the publisher.
    The authors declare that the research was conducted in the
absence of any commercial or ﬁnancial relationships that could be
construed as a potential conﬂict of interest.
                                                                                                Supplementary material
Generative AI statement
                                                                                                     The Supplementary Material for this article can be found online
    The author(s) declare that no Generative AI was used in the                                 at: https://www.frontiersin.org/articles/10.3389/fendo.2025.1552219/
creation of this manuscript.                                                                    full#supplementary-material




References
  1. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al.                    15. Weichhart T, Kopecky C, Kubicek M, Haidinger M, Döller D, Katholnig K, et al.
Cardiovascular-kidney-metabolic health: A presidential advisory from the american               Serum amyloid A in uremic HDL promotes inﬂammation. J Am Soc Nephrol: JASN.
heart association. Circulation (2023) 148:1606–35. doi: 10.1161/                                (2012) 23:934–47. doi: 10.1681/asn.2011070668
CIR.0000000000001184                                                                              16. Zheng G, Jin J, Wang F, Zheng Q, Shao J, Yao J, et al. Association between
  2. Malik S, Wong ND, Franklin SS, Kamath TV, L’Italien GJ, Pio JR, et al. Impact of           atherogenic index of plasma and future risk of cardiovascular disease in individuals
the metabolic syndrome on mortality from coronary heart disease, cardiovascular                 with cardiovascular-kidney-metabolic syndrome stages 0-3: a nationwide prospective
disease, and all causes in United States adults. Circulation (2004) 110:1245–50.                cohort study. Cardiovasc Diabetol. (2025) 24:22. doi: 10.1186/s12933-025-02589-9
doi: 10.1161/01.CIR.0000140677.20606.0E                                                            17. Li N, Li Y, Cui L, Shu R, Song H, Wang J, et al. Association between different
  3. Ostrominski JW, Arnold SV, Butler J, Fonarow GC, Hirsch JS, Palli SR, et al.               stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality.
Prevalence and overlap of cardiac, renal, and metabolic conditions in US adults, 1999-          Atherosclerosis. (2024) 397:118585. doi: 10.1016/j.atherosclerosis.2024.118585
2020. JAMA Cardiol. (2023) 8:1050–60. doi: 10.1001/jamacardio.2023.3241                           18. Güven R, Akyol KC, Bayar N, Güngör F, Akça AH, Ç elik A. Neutrophil count as
  4. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al.             a predictor of critical coronary artery stenosis in young patients. Iranian J Public
Triglycerides and the risk of coronary heart disease. Circulation (2007) 115:450–8.             Health. (2018) 47:765–7.
doi: 10.1161/CIRCULATIONAHA.106.637793                                                            19. Makrygiannis SS, Ampartzidou OS, Zairis MN, Patsourakos NG, Pitsavos C,
  5. Prenner SB, Mulvey CK, Ferguson JF, Rickels MR, Bhatt AB, Reilly MP. Very low              Tousoulis D, et al. Prognostic usefulness of serial C-reactive protein measurements in
density lipoprotein cholesterol associates with coronary artery calciﬁcation in type 2          ST-elevation acute myocardial infarction. Am J Cardiol. (2013) 111:26–30.
diabetes beyond circulating levels of triglycerides. Atherosclerosis. (2014) 236:244–50.        doi: 10.1016/j.amjcard.2012.08.041
doi: 10.1016/j.atherosclerosis.2014.07.008                                                        20. Liu W, Weng S, Cao C, Yi Y, Wu Y, Peng D. Association between monocyte-
  6. Collaboration* TERF. Major lipids, apolipoproteins, and risk of vascular disease.          lymphocyte ratio and all-cause and cardiovascular mortality in patients with chronic
JAMA. (2009) 302:1993–2000. doi: 10.1001/jama.2009.1619                                         kidney diseases: A data analysis from national health and nutrition examination survey
   7. Li W, Shen C, Kong W, Zhou X, Fan H, Zhang Y, et al. Association between the              (NHANES) 2003-2010. Renal Failure. (2024) 46:2352126. doi: 10.1080/
triglyceride glucose-body mass index and future cardiovascular disease risk in a                0886022x.2024.2352126
population with Cardiovascular-Kidney-Metabolic syndrome stage 0-3: a nationwide                  21. Gao C, Gao S, Zhao R, Shen P, Zhu X, Yang Y, et al. Association between
prospective cohort study. Cardiovasc Diabetol. (2024) 23:292. doi: 10.1186/s12933-024-          systemic immune-inﬂammation index and cardiovascular-kidney-metabolic
02352-6                                                                                         syndrome. Sci Rep. (2024) 14:19151. doi: 10.1038/s41598-024-69819-0
  8. Tian J, Chen H, Luo Y, Zhang Z, Xiong S, Liu H. Association between estimated                22. D’Elia JA, Weinrauch LA. Lipid toxicity in the cardiovascular-kidney-metabolic
glucose disposal rate and prediction of cardiovascular disease risk among individuals           syndrome (CKMS). Biomedicines (2024) 12:978. doi: 10.3390/biomedicines12050978
with cardiovascular-kidney-metabolic syndrome stage 0-3: a nationwide prospective                  23. Janota O, Mantovani M, Kwiendacz H, Irlik K, Bucci T, Lam SHM, et al.
cohort study. Diabetol Metab Syndrome. (2025) 17:58. doi: 10.1186/s13098-025-01626-             Metabolically “extremely unhealthy” obese and non-obese people with diabetes and the
7                                                                                               risk of cardiovascular adverse events: the Silesia Diabetes - Heart Project. Cardiovasc
  9. Kou T, Luo H, Yin L. Relationship between neutrophils to HDL-C ratio and                   Diabetol. (2024) 23:326. doi: 10.1186/s12933-024-02420-x
severity of coronary stenosis. BMC Cardiovasc Disord. (2021) 21:127. doi: 10.1186/                24. Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G. Biomarkers of
s12872-020-01771-z                                                                              inﬂammation and progression of chronickidney disease. Kidney Int. (2005) 68:237–
  10. Chen Y, Dong J, Chen X, Jiang H, Bakillah A, Zhang X, et al. Human serum                  45. doi: 10.1111/j.1523-1755.2005.00398.x
preb1-high density lipoprotein levels are independently and negatively associated with            25. Zhang D-P, Baituola G, Wu T-T, Chen Y, Hou X-G, Yang Y, et al. An elevated
coronary artery diseases. Nutr Metab. (2016) 13:36. doi: 10.1186/s12986-016-0093-y              monocyte-to-high-density lipoprotein–cholesterol ratio is associated with mortality in
   11. Reiss AB, Voloshyna I, De Leon J, Miyawaki N, Mattana J. Cholesterol                     patients with coronary artery disease who have undergone PCI. Biosci Rep. (2020) 40.
metabolism in CKD. Am J Kidney Dis. (2015) 66:1071–82. doi: 10.1053/                            doi: 10.1042/bsr20201108
j.ajkd.2015.06.028                                                                                 26. Wu T-T, Zheng Y-Y, Xiu W-J, Wang W-R, Xun Y-L, Ma Y-Y, et al. White blood
  12. Holzer M, Birner-Gruenberger R, Stojakovic T, El-Gamal D, Binder V, Wadsack               cell counts to high-density lipoprotein cholesterol ratio, as a novel predictor of long-
C, et al. Uremia alters HDL composition and function. J Am Soc Nephrol: JASN. (2011)            term adverse outcomes in patients after percutaneous coronary intervention: A
22:1631–41. doi: 10.1681/asn.2010111144                                                         retrospective cohort study. Front Cardiovasc Med. (2021) 8. doi: 10.3389/
  13. Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic              fcvm.2021.616896
predialysis and hemodialysis patients. J Nephrol. (2004) 17:813–8.                                27. Lin J, Li Z, Xu J, Pan M, Yin T, Wang J, et al. Independent and joint associations
  14. Dantoine TF, Debord J, Charmes JP, Merle L, Marquet P, Lachatre G, et al.                 of monocyte to high-density lipoprotein-cholesterol ratio and body mass index with
Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol:              cardiorenal syndrome: insights from NHANES 2003–2020. Lipids Health Dis. (2024)
JASN. (1998) 9:2082–8. doi: 10.1681/asn.V9112082                                                23:153. doi: 10.1186/s12944-024-02149-2




Frontiers in Endocrinology                                                                 13                                                                          frontiersin.org
Han et al.                                                                                                                                          10.3389/fendo.2025.1552219




  28. Gao Y, Wang M, Wang R, Jiang J, Hu Y, Wang W, et al. The predictive value of                38. Luwen H, Lei X, Qing-Rong O, Linlin L, Ming Y. Association between hs-CRP/
the hs-CRP/HDL-C ratio, an inﬂammation-lipid composite marker, for cardiovascular              HDL-C ratio and three-month unfavorable outcomes in patients with acute ischemic
disease in middle-aged and elderly people: evidence from a large national cohort study.        stroke: a second analysis based on a prospective cohort study. BMC Neurol. (2024)
Lipids Health Dis. (2024) 23:66. doi: 10.1186/s12944-024-02055-7                               24:418. doi: 10.1186/s12883-024-03929-0
   29. Zhao Y, Hu Y, Smith JP, Strauss J, Yang G. Cohort proﬁle: the China health and            39. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive
retirement longitudinal study (CHARLS). Int J Epidemiol. (2012) 43:61–8. doi: 10.1093/         protein and complement components in atherosclerotic plaques. Am J Pathol. (2001)
ije/dys203                                                                                     158:1039–51. doi: 10.1016/s0002-9440(10)64051-5
  30. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al.                 40. Singh U, Devaraj S, Dasu MR, Ciobanu D, Reusch J, Jialal I. C-reactive protein
General cardiovascular risk proﬁle for use in primary care. Circulation (2008) 117:743–        decreases interleukin-10 secretion in activated human monocyte-derived macrophages
53. doi: 10.1161/CIRCULATIONAHA.107.699579                                                     via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol (2006)
  31. Ma Y-C, Zuo L, Chen J-H, Luo Q, Yu X-Q, Li Y, et al. Modiﬁed glomerular                  26:2469–75. doi: 10.1161/01.ATV.0000241572.05292.fb
ﬁltration rate estimating equation for chinese patients with chronic kidney disease. J           41. Alsaffar H, Martino N, Garrett JP, Adam AP. Interleukin-6 promotes a sustained
Am Soc Nephrol (2006) 17:2937–44. doi: 10.1681/asn.2006040368                                  loss of endothelial barrier function via Janus kinase-mediated STAT3 phosphorylation
   32. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J,            and de novo protein synthesis. Am J Physiol Cell Physiol (2018) 314:C589–602.
et al. Evidence-Based guideline for the management of high blood pressure in adults:           doi: 10.1152/ajpcell.00235.2017
report from the panel members appointed to the eighth joint national committee (JNC 8).          42. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res.
JAMA. (2014) 311:507–20. doi: 10.1001/jama.2013.284427                                         (1968) 9:155–67. doi: 10.1016/S0022-2275(20)43114-1
   33. American Diabetes Association. Classiﬁcation and diagnosis of diabetes:                   43. Brewer HB. Increasing HDL cholesterol levels. N Engl J Med (2004) 350:1491–4.
standards of medical care in diabetes-2020. Diabetes Care. (2020) 43. doi: 10.2337/            doi: 10.1056/NEJMp048023
dc20-S002                                                                                        44. Kosmas CE, Martinez I, Sourlas A, Bouza KV, Campos FN, Torres V, et al. High-
   34. Yang P, Xiao Y, Luo X, Zhao Y, Zhao L, Wang Y, et al. Inﬂammatory stress                density lipoprotein (HDL) functionality and its relevance to atherosclerotic
promotes the development of obesity-related chronic kidney disease via CD36 in mice.           cardiovascular disease. Drugs Context. (2018) 7:212525. doi: 10.7573/dic.212525
J Lipid Res. (2017) 58:1417–27. doi: 10.1194/jlr.M076216                                         45. Yin K, Chen W-J, Zhou Z-G, Zhao G-J, Lv Y-C, Ouyang X-P, et al.
  35. Gao X, Wu J, Qian Y, Fu L, Wu G, Xu C, et al. Oxidized high-density lipoprotein          Apolipoprotein A-I inhibits CD40 proinﬂammatory signaling via ATP-binding
impairs the function of human renal proximal tubule epithelial cells through CD36. Int         cassette transporter A1-mediated modulation of lipid raft in macrophages. J
J Mol Med. (2014) 34:564–72. doi: 10.3892/ijmm.2014.1799                                       Atheroscl Thrombosis. (2012) 19:823–36. doi: 10.5551/jat.12823
  36. Kennedy DJ, Chen Y, Huang W, Viterna J, Liu J, Westfall K, et al. CD36 and na/             46. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M,
K-ATPase-a1 form a proinﬂammatory signaling loop in kidney. Hypertension. (2013)               Jensen MK, et al. Plasma HDL cholesterol and risk of myocardial infarction: a
61:216–24. doi: 10.1161/HYPERTENSIONAHA.112.198770                                             mendelian randomisation study. Lancet. (2012) 380:572–80. doi: 10.1016/S0140-6736
  37. Yano M, Nishino M, Ukita K, Kawamura A, Nakamura H, Matsuhiro Y, et al.                  (12)60312-2
High density lipoprotein cholesterol/C reactive protein ratio in heart failure with               47. Kang BA, Li HM, Chen YT, Deng MJ, Li Y, Peng YM, et al. High-density
preserved ejection fraction. ESC Heart Failure. (2021) 8:2791–801. doi: 10.1002/               lipoprotein regulates angiogenesis by affecting autophagy via miRNA-181a-5p. Sci
ehf2.13350                                                                                     China Life Sci. (2024) 67:286–300. doi: 10.1007/s11427-022-2381-7




Frontiers in Endocrinology                                                                14                                                                          frontiersin.org

```
